

# Sexually Transmitted Disease Surveillance January–July 2024: Enhanced Gonococcal Isolate Surveillance Project Profile

Division of STD Prevention  
September 2025

**NOTE:** The Enhanced Gonococcal Isolate Surveillance Project (eGISP) ended on July 31, 2024. On August 1, 2024, CDC began the Combatting Antimicrobial Resistant Gonorrhea and Other STIs (CARGOS) project. The activities conducted under eGISP were incorporated into CARGOS and any antimicrobial resistant gonorrhea data collected after August 1, 2024 will be reported in CARGOS Profiles.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
CENTERS FOR DISEASE CONTROL AND PREVENTION  
NATIONAL CENTER FOR HIV, VIRAL HEPATITIS, STD, AND TB PREVENTION  
DIVISION OF STD PREVENTION  
ATLANTA, GEORGIA 30329-4027

## Acknowledgments

2

Publication of this report would not have been possible without the contributions of all participating state and local health departments, sexually transmitted disease clinics, public health laboratories, and regional laboratories.

This report was prepared by:

Sammie Haskin, Alesia Harvey, Rebekah Frankson, Kristen Kreisel, Emily Rowlinson, and Luke Shouse, Surveillance and Data Science Branch of the Division of STD Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention.

Additional contributions by Matthew Schmerer, Myriam Bèlanger, and Ellen Kersh, STD Laboratory Reference and Research Branch of the Division of STD Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, and LaShondra Berman and Eboni Galloway, Behavioral Science and Epidemiology Branch of the Division of STD Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention.

## Copyright Information

All material contained in this report is in the public domain and may be used and reprinted without special permission; however, citation as to source is appreciated.

## Suggested Citation

Centers for Disease Control and Prevention. *Sexually Transmitted Disease Surveillance January-July 2024: Enhanced Gonococcal Isolate Surveillance Project National Profile*. Atlanta: U.S. Department of Health and Human Services; 2025.

## Web Site

The online version of this report is available at <https://www.cdc.gov/sti-statistics/qisp-profiles/>.

## Technical Note

Antimicrobial susceptibility data presented in this report are based on criteria established by the Clinical & Laboratory Standards Institute (CLSI) and the FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria (FDA-STIC).

**2024 Enhanced Gonococcal Isolate Surveillance Project  
Clinical Sites and Years Participated**

Columbus, Ohio <i>(2018-2019, 2023-2024)</i>	Orange County, California <i>(2018–2024)</i>
Honolulu, Hawaii <i>(2023-2024)</i>	Philadelphia, Pennsylvania <i>(2018–2024)</i>
Las Vegas, Nevada <i>(2018–2024)</i>	Phoenix, Arizona <i>(2020–2024)</i>
Minneapolis, Minnesota <i>(2018–2019,2023-2024)</i>	San Diego, California <i>(2018–2024)</i>
New Orleans, Louisiana <i>(2018–2024)</i>	

**2024 Enhanced Gonococcal Isolate Surveillance Project Regional Laboratories**


Maryland Department of Health and Mental Hygiene <i>Baltimore, Maryland</i>
Tennessee Department of Health <i>Nashville, Tennessee</i>
Utah Department of Health <i>Salt Lake City, Utah</i>
Washington State Department of Health <i>Seattle, Washington</i>

## **2024 Enhanced Gonococcal Isolate Surveillance Project Profiles**

### **Table of Contents**

Figure 1.	<a href="#"><u>Number of <i>Neisseria gonorrhoeae</i> Isolates by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), January 1, 2022-July 31, 2024.</u></a>	5
Figure 2.	<a href="#"><u>Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among <i>Neisseria gonorrhoeae</i> Isolate by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), January 1, 2022-July 31, 2024.</u></a>	6
Figure 3.	<a href="#"><u>Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among <i>Neisseria gonorrhoeae</i> Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), January 1, 2022-July 31, 2024.</u></a>	7
Figure 4.	<a href="#"><u>Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among <i>Neisseria gonorrhoeae</i> Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), January 1, 2022-July 31, 2024.</u></a>	8
Figure 5.	<a href="#"><u>Distribution of Ciprofloxacin Minimum Inhibitory Concentrations (MICs) Among <i>Neisseria gonorrhoeae</i> Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), January 1, 2022-July 31, 2024.</u></a>	9
Figure 6.	<a href="#"><u>Distribution of Gentamicin Minimum Inhibitory Concentrations (MICs) Among <i>Neisseria gonorrhoeae</i> Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), January 1, 2022-July 31, 2024.</u></a>	10
Figure 7.	<a href="#"><u>Distribution of Penicillin Minimum Inhibitory Concentrations (MICs) Among <i>Neisseria gonorrhoeae</i> Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), January 1, 2022-July 31, 2024.</u></a>	11
Figure 8.	<a href="#"><u>Distribution of Tetracycline Minimum Inhibitory Concentrations (MICs) Among <i>Neisseria gonorrhoeae</i> Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), January 1, 2022-July 31, 2024.</u></a>	12
Figure 9.	<a href="#"><u>Percentage of <i>Neisseria gonorrhoeae</i> Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Cefixime by Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), January 1, 2022-July 31, 2024.</u></a>	13
Figure 10.	<a href="#"><u>Percentage of <i>Neisseria gonorrhoeae</i> Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Ceftriaxone by Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), January 1, 2022-July 31, 2024.</u></a>	14
Figure 11.	<a href="#"><u>Percentage of <i>Neisseria gonorrhoeae</i> Isolates with Resistance to Azithromycin by Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), January 1, 2022-July 31, 2024.</u></a>	15
Figure 12.	<a href="#"><u>Percentage of <i>Neisseria gonorrhoeae</i> Isolates with Resistance to Ciprofloxacin by Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), January 1, 2022-July 31, 2024.</u></a>	16
Figure 13.	<a href="#"><u>Percentage of <i>Neisseria gonorrhoeae</i> Isolates with Resistance to Penicillin by Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), January 1, 2022-July 31, 2024.</u></a>	17
Figure 14.	<a href="#"><u>Percentage of <i>Neisseria gonorrhoeae</i> Isolates with Resistance to Tetracycline by Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), January 1, 2022-July 31, 2024.</u></a>	18


Figure 1. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), January 1, 2022-July 31, 2024



Site of Infection	Year	MSM	MSW	Women	Total
Genital	2022	333	580	67	980
Genital	2023	380	534	60	974
Genital	2024	189	322	37	548
Pharyngeal	2022	136	34	43	213
Pharyngeal	2023	151	27	30	208
Pharyngeal	2024	106	16	23	145
Rectal	2022	233	3	10	246
Rectal	2023	222	1	7	230
Rectal	2024	116	2	6	124

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Figure 2. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), January 1, 2022-July 31, 2024



Site of Infection	Year	≤0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	Total
Genital	2022	702 (70.8)	226 (22.8)	32 (3.2)	30 (3.0)	2 (0.2)	0 (0.0)	0 (0.0)	0 (0.0)	992
Genital	2023	690 (68.5)	183 (18.2)	49 (4.9)	80 (7.9)	5 (0.5)	0 (0.0)	0 (0.0)	1 (0.1)	1008
Genital	2024	410 (73.1)	64 (11.4)	32 (5.7)	48 (8.6)	5 (0.9)	2 (0.4)	0 (0.0)	0 (0.0)	561
Pharyngeal	2022	140 (63.1)	59 (26.6)	8 (3.6)	15 (6.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	222
Pharyngeal	2023	135 (59.2)	46 (20.2)	22 (9.6)	22 (9.6)	3 (1.3)	0 (0.0)	0 (0.0)	0 (0.0)	228
Pharyngeal	2024	101 (66.4)	16 (10.5)	10 (6.6)	24 (15.8)	1 (0.7)	0 (0.0)	0 (0.0)	0 (0.0)	152
Rectal	2022	150 (57.9)	75 (29.0)	12 (4.6)	21 (8.1)	0 (0.0)	0 (0.0)	1 (0.4)	0 (0.0)	259
Rectal	2023	164 (63.3)	49 (18.9)	20 (7.7)	23 (8.9)	3 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	259
Rectal	2024	96 (68.1)	11 (7.8)	14 (9.9)	19 (13.5)	1 (0.7)	0 (0.0)	0 (0.0)	0 (0.0)	141

GISP Alert Value = cefixime MIC  $\geq 0.25$  µg/mL; CLSI Non-susceptible = cefixime MIC  $\geq 0.5$  µg/mL.


CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of publication, the CLSI has not established a cefixime resistance breakpoint for *N. gonorrhoeae*.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Figure 3. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), January 1, 2022-July 31, 2024



Site of Infection	Year	≤0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2022	671 (67.6)	282 (28.4)	35 (3.5)	4 (0.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	992
Genital	2023	636 (63.1)	274 (27.2)	88 (8.7)	9 (0.9)	0 (0.0)	1 (0.1)	0 (0.0)	0 (0.0)	1008
Genital	2024	366 (65.2)	138 (24.6)	47 (8.4)	8 (1.4)	1 (0.2)	1 (0.2)	0 (0.0)	0 (0.0)	561
Pharyngeal	2022	139 (62.6)	71 (32.0)	12 (5.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	222
Pharyngeal	2023	111 (48.7)	81 (35.5)	33 (14.5)	3 (1.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	228
Pharyngeal	2024	89 (58.6)	51 (33.6)	12 (7.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	152
Rectal	2022	150 (57.9)	92 (35.5)	15 (5.8)	1 (0.4)	0 (0.0)	0 (0.0)	1 (0.4)	0 (0.0)	259
Rectal	2023	143 (55.2)	86 (33.2)	24 (9.3)	5 (1.9)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.4)	259
Rectal	2024	88 (62.4)	40 (28.4)	13 (9.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	141

GISP Alert Value = ceftriaxone MIC ≥0.125 µg/mL; CLSI Non-susceptible = ceftriaxone MIC ≥0.5 µg/mL.


CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of publication, the CLSI has not established a ceftriaxone resistance breakpoint for *N. gonorrhoeae*.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Figure 4. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), January 1, 2022-July 31, 2024



Site of Infection	Year	≤0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥16.0 n (%)	Total
Genital	2022	222 (22.4)	506 (51.0)	103 (10.4)	120 (12.1)	35 (3.5)	1 (0.1)	3 (0.3)	2 (0.2)	992
Genital	2023	157 (15.6)	541 (53.7)	102 (10.1)	139 (13.8)	54 (5.4)	1 (0.1)	9 (0.9)	5 (0.5)	1008
Genital	2024	80 (14.3)	330 (58.8)	34 (6.1)	71 (12.7)	38 (6.8)	0 (0.0)	6 (1.1)	2 (0.4)	561
Pharyngeal	2022	36 (16.2)	119 (53.6)	19 (8.6)	31 (14.0)	9 (4.1)	1 (0.5)	3 (1.4)	4 (1.8)	222
Pharyngeal	2023	19 (8.3)	117 (51.3)	26 (11.4)	40 (17.5)	22 (9.6)	0 (0.0)	0 (0.0)	4 (1.8)	228
Pharyngeal	2024	11 (7.2)	88 (57.9)	9 (5.9)	26 (17.1)	16 (10.5)	1 (0.7)	0 (0.0)	1 (0.7)	152
Rectal	2022	33 (12.7)	142 (54.8)	21 (8.1)	41 (15.8)	19 (7.3)	1 (0.4)	0 (0.0)	2 (0.8)	259
Rectal	2023	20 (7.7)	155 (59.8)	36 (13.9)	29 (11.2)	17 (6.6)	0 (0.0)	0 (0.0)	2 (0.8)	259
Rectal	2024	12 (8.5)	87 (61.7)	14 (9.9)	19 (13.5)	9 (6.4)	0 (0.0)	0 (0.0)	0 (0.0)	141


GISP Alert Value: azithromycin MIC ≥2.0 µg/mL; FDA-STIC Resistant = azithromycin MIC ≥2.0 µg/mL.

FDA-STIC = FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria.

In 2025, azithromycin resistance was established as ≥2.0 µg/mL (FDA-STIC).

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Figure 5. Distribution of Ciprofloxacin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), January 1, 2022-July 31, 2024




Site of Infection	Year	≤0.015 n (%)	0.03-0.06 n (%)	0.125 n (%)	0.25-0.5 n (%)	1.0-2.0 n (%)	≥4.0 n (%)	Total
Genital	2022	576 (58.1)	14 (1.4)	16 (1.6)	66 (6.7)	78 (7.9)	242 (24.4)	992
Genital	2023	485 (48.1)	17 (1.7)	5 (0.5)	99 (9.8)	103 (10.2)	299 (29.7)	1008
Genital	2024	295 (52.6)	10 (1.8)	1 (0.2)	43 (7.7)	49 (8.7)	163 (29.1)	561
Pharyngeal	2022	122 (55.0)	1 (0.5)	3 (1.4)	8 (3.6)	20 (9.0)	68 (30.6)	222
Pharyngeal	2023	97 (42.5)	3 (1.3)	1 (0.4)	11 (4.8)	23 (10.1)	93 (40.8)	228
Pharyngeal	2024	63 (41.4)	1 (0.7)	0 (0.0)	6 (3.9)	20 (13.2)	62 (40.8)	152
Rectal	2022	125 (48.3)	3 (1.2)	2 (0.8)	17 (6.6)	31 (12.0)	81 (31.3)	259
Rectal	2023	102 (39.4)	4 (1.5)	2 (0.8)	31 (12.0)	19 (7.3)	101 (39.0)	259
Rectal	2024	53 (37.6)	0 (0.0)	0 (0.0)	14 (9.9)	22 (15.6)	52 (36.9)	141

Ciprofloxacin resistance MIC ≥1.0 µg/mL.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.


Figure 6. Distribution of Gentamicin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), January 1, 2022-July 31, 2024



Site of Infection	Year	0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	16.0 n (%)	≥32.0 n (%)	Total
Genital	2022	0 (0.0)	0 (0.0)	5 (0.5)	13 (1.3)	168 (16.9)	778 (78.4)	28 (2.8)	0 (0.0)	992
Genital	2023	0 (0.0)	0 (0.0)	3 (0.3)	12 (1.2)	160 (15.9)	716 (71.0)	107 (10.6)	10 (1.0)	1008
Genital	2024	0 (0.0)	0 (0.0)	0 (0.0)	13 (2.3)	76 (13.5)	448 (79.9)	24 (4.3)	0 (0.0)	561
Pharyngeal	2022	0 (0.0)	0 (0.0)	0 (0.0)	3 (1.4)	48 (21.6)	164 (73.9)	7 (3.2)	0 (0.0)	222
Pharyngeal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	28 (12.3)	178 (78.1)	22 (9.6)	0 (0.0)	228
Pharyngeal	2024	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.7)	27 (17.8)	117 (77.0)	7 (4.6)	0 (0.0)	152
Rectal	2022	0 (0.0)	0 (0.0)	0 (0.0)	2 (0.8)	43 (16.6)	200 (77.2)	14 (5.4)	0 (0.0)	259
Rectal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	24 (9.3)	219 (84.6)	15 (5.8)	1 (0.4)	259
Rectal	2024	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	20 (14.2)	113 (80.1)	8 (5.7)	0 (0.0)	141

As of publication, the Clinical & Laboratory Standards Institute (CLSI) criteria for susceptibility and resistance to gentamicin have not been established for *N. gonorrhoeae*. A GISP alert value for gentamicin has not been determined. Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.


Figure 7. Distribution of Penicillin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), January 1, 2022-July 31, 2024



Site of Infection	Year	≤0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥16.0 n (%)	Total
Genital	2022	66 (6.7)	364 (36.7)	356 (35.9)	111 (11.2)	30 (3.0)	23 (2.3)	18 (1.8)	24 (2.4)	992
Genital	2023	44 (4.4)	363 (36.0)	318 (31.5)	102 (10.1)	56 (5.6)	41 (4.1)	38 (3.8)	46 (4.6)	1008
Genital	2024	18 (3.2)	192 (34.2)	159 (28.3)	50 (8.9)	43 (7.7)	29 (5.2)	38 (6.8)	32 (5.7)	561
Pharyngeal	2022	6 (2.7)	69 (31.1)	81 (36.5)	34 (15.3)	13 (5.9)	7 (3.2)	4 (1.8)	8 (3.6)	222
Pharyngeal	2023	5 (2.2)	76 (33.3)	71 (31.1)	32 (14.0)	12 (5.3)	10 (4.4)	11 (4.8)	11 (4.8)	228
Pharyngeal	2024	1 (0.7)	37 (24.3)	45 (29.6)	15 (9.9)	16 (10.5)	14 (9.2)	14 (9.2)	10 (6.6)	152
Rectal	2022	12 (4.6)	68 (26.3)	95 (36.7)	36 (13.9)	16 (6.2)	6 (2.3)	13 (5.0)	13 (5.0)	259
Rectal	2023	4 (1.5)	101 (39.0)	81 (31.3)	19 (7.3)	19 (7.3)	11 (4.2)	13 (5.0)	11 (4.2)	259
Rectal	2024	0 (0.0)	36 (25.5)	33 (23.4)	9 (6.4)	14 (9.9)	18 (12.8)	14 (9.9)	17 (12.1)	141

Penicillin resistance based on Clinical & Laboratory Standards Institute (CLSI) MIC criteria only (MIC ≥2.0 µg/mL).  
 Additional data on β-lactamase positivity are not depicted.  
 Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Figure 8. Distribution of Tetracycline Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), January 1, 2022-July 31, 2024




Site of Infection	Year	0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥16.0 n (%)	Total
Genital	2022	4 (0.4)	107 (10.8)	233 (23.5)	470 (47.4)	45 (4.5)	8 (0.8)	4 (0.4)	121 (12.2)	992
Genital	2023	0 (0.0)	92 (9.1)	173 (17.2)	488 (48.4)	48 (4.8)	4 (0.4)	0 (0.0)	203 (20.1)	1008
Genital	2024	0 (0.0)	54 (9.6)	87 (15.5)	233 (41.5)	14 (2.5)	7 (1.2)	1 (0.2)	165 (29.4)	561
Pharyngeal	2022	0 (0.0)	21 (9.5)	43 (19.4)	109 (49.1)	8 (3.6)	1 (0.5)	1 (0.5)	39 (17.6)	222
Pharyngeal	2023	0 (0.0)	15 (6.6)	29 (12.7)	116 (50.9)	14 (6.1)	2 (0.9)	0 (0.0)	52 (22.8)	228
Pharyngeal	2024	0 (0.0)	8 (5.3)	16 (10.5)	65 (42.8)	6 (3.9)	0 (0.0)	0 (0.0)	57 (37.5)	152
Rectal	2022	0 (0.0)	27 (10.4)	34 (13.1)	133 (51.4)	10 (3.9)	0 (0.0)	3 (1.2)	52 (20.1)	259
Rectal	2023	0 (0.0)	16 (6.2)	29 (11.2)	145 (56.0)	11 (4.2)	1 (0.4)	0 (0.0)	57 (22.0)	259
Rectal	2024	0 (0.0)	4 (2.8)	15 (10.6)	48 (34.0)	3 (2.1)	0 (0.0)	1 (0.7)	70 (49.6)	141

Tetracycline resistance MIC ≥2.0 µg/mL.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.


Figure 9. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Cefixime by Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), January 1, 2022-July 31, 2024



Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2022	0 (0.0)	2 (0.3)	0 (0.0)	2
Genital	2023	1 (0.3)	5 (0.9)	0 (0.0)	6
Genital	2024	3 (1.6)	3 (0.9)	1 (2.7)	7
Pharyngeal	2022	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2023	2 (1.3)	0 (0.0)	1 (3.3)	3
Pharyngeal	2024	1 (0.9)	0 (0.0)	0 (0.0)	1
Rectal	2022	1 (0.4)	0 (0.0)	0 (0.0)	1
Rectal	2023	3 (1.4)	0 (0.0)	0 (0.0)	3
Rectal	2024	1 (0.9)	0 (0.0)	0 (0.0)	1

MSM = Men who have sex with men; MSW = Men who have sex with women only.  
 Cefixime elevated MIC  $\geq 0.25$   $\mu\text{g}/\text{mL}$ .  
 Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Figure 10. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ceftriaxone by Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), January 1, 2022-July 31, 2024




Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2022	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2023	0 (0.0)	1 (0.2)	0 (0.0)	1
Genital	2024	2 (1.1)	0 (0.0)	0 (0.0)	2
Pharyngeal	2022	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2024	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2022	1 (0.4)	0 (0.0)	0 (0.0)	1
Rectal	2023	1 (0.5)	0 (0.0)	0 (0.0)	1
Rectal	2024	0 (0.0)	0 (0.0)	0 (0.0)	0

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Ceftriaxone elevated MIC  $\geq 0.125$   $\mu\text{g/mL}$ .

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.


Figure 11. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Azithromycin by Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), January 1, 2022-July 31, 2024



Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2022	21 (6.3)	18 (3.1)	2 (3.0)	41
Genital	2023	27 (7.1)	33 (6.2)	5 (8.3)	65
Genital	2024	13 (6.9)	29 (9.0)	1 (2.7)	43
Pharyngeal	2022	11 (8.1)	2 (5.9)	4 (9.3)	17
Pharyngeal	2023	18 (11.9)	4 (14.8)	3 (10.0)	25
Pharyngeal	2024	12 (11.3)	0 (0.0)	4 (17.4)	16
Rectal	2022	19 (8.2)	1 (33.3)	1 (10.0)	21
Rectal	2023	14 (6.3)	0 (0.0)	2 (28.6)	16
Rectal	2024	6 (5.2)	0 (0.0)	1 (16.7)	7

MSM = Men who have sex with men; MSW = Men who have sex with women only.  
 Azithromycin resistance  $\geq 2.0$   $\mu\text{g/mL}$ . (In 2025, FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria established azithromycin resistance as  $\geq 2.0$   $\mu\text{g/mL}$ ).  
 Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Figure 12. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin by Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), January 1, 2022-July 31, 2024




Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2022	131 (39.3)	164 (28.3)	21 (31.3)	316
Genital	2023	182 (47.9)	181 (33.9)	23 (38.3)	386
Genital	2024	91 (48.1)	101 (31.4)	15 (40.5)	207
Pharyngeal	2022	60 (44.1)	13 (38.2)	11 (25.6)	84
Pharyngeal	2023	82 (54.3)	10 (37.0)	14 (46.7)	106
Pharyngeal	2024	62 (58.5)	6 (37.5)	9 (39.1)	77
Rectal	2022	99 (42.5)	0 (0.0)	3 (30.0)	102
Rectal	2023	101 (45.5)	0 (0.0)	4 (57.1)	105
Rectal	2024	60 (51.7)	1 (50.0)	2 (33.3)	63

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Ciprofloxacin resistance = MIC ≥1.0 µg/mL.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.


Figure 13. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Penicillin by Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), January 1, 2022-July 31, 2024



Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2022	57 (17.1)	46 (7.9)	6 (9.0)	109
Genital	2023	111 (29.2)	74 (13.9)	5 (8.3)	190
Genital	2024	76 (40.2)	70 (21.7)	5 (13.5)	151
Pharyngeal	2022	23 (16.9)	8 (23.5)	3 (7.0)	34
Pharyngeal	2023	35 (23.2)	2 (7.4)	3 (10.0)	40
Pharyngeal	2024	43 (40.6)	6 (37.5)	4 (17.4)	53
Rectal	2022	50 (21.5)	0 (0.0)	2 (20.0)	52
Rectal	2023	48 (21.6)	0 (0.0)	0 (0.0)	48
Rectal	2024	57 (49.1)	1 (50.0)	0 (0.0)	58

MSM = Men who have sex with men; MSW = Men who have sex with women only.  
 Penicillin resistance  $\geq 2.0$   $\mu\text{g/mL}$  or  $\beta$ -lactamase positive.  
 Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Figure 14. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Tetracycline by Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), January 1, 2022-July 31, 2024



Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2022	85 (25.5)	80 (13.8)	8 (11.9)	173
Genital	2023	139 (36.6)	98 (18.4)	9 (15.0)	246
Genital	2024	96 (50.8)	81 (25.2)	5 (13.5)	182
Pharyngeal	2022	30 (22.1)	10 (29.4)	7 (16.3)	47
Pharyngeal	2023	47 (31.1)	4 (14.8)	7 (23.3)	58
Pharyngeal	2024	51 (48.1)	7 (43.8)	4 (17.4)	62
Rectal	2022	57 (24.5)	0 (0.0)	2 (20.0)	59
Rectal	2023	60 (27.0)	0 (0.0)	1 (14.3)	61
Rectal	2024	62 (53.4)	1 (50.0)	2 (33.3)	65

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Tetracycline resistance  $\geq 2.0$   $\mu\text{g/mL}$ .

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.